Front Line Genomics
It’s estimated that 90% of dying cancer patients die from cancer metastasis. There is currently no cure. Less than 5% of cancer funds go towards tackling metastatic cancer. That’s a
It’s estimated that 90% of dying cancer patients die from cancer metastasis. There is currently no cure. Less than 5% of cancer funds go towards tackling metastatic cancer. That’s a dire situation for cancer patients and their families, and it needs to change. Unlike some other existing (and fantastic) research-oriented metastatic cancer events, this event is the first to move beyond basic research and focus on the development of effective therapies.
Given the urgency of this event, it is crucial that the right people are there. This event will bring together the entire oncology community – pharma, researchers, clinicians, and advocates– to create meaningful change for patients. Our speakers include cancer research pioneers such as Bob Weinberg and Bob Kerbel as well as global leaders and decision-makers in translational oncology. This meeting will address a range of incredible new therapeutic opportunities in a friendly, welcoming environment conducive to deep learning and networking.
Key Benefits of Attending:
• Explore some of the latest scientific insights into the complex metastatic cascade, and gain insight into the most promising therapeutic avenues for drug developers to explore in the near term.
• Learn from the successes and failures in metastasis research, with the hope of fostering collaboration throughout the drug discovery pipeline.
• Realize how pharma can rise to the challenge and work with experts in pre-clinical modelling to prioritise pre-clinical testing for metastasis.
• Hear case studies from experts in immuno-oncology, to understand how we can overcome some of the biggest barriers in translation.
Nov. 20 to Nov. 21
Hyatt Regency Downtown Boston
One Avenue de Lafayette
Boston, MA 02111